Literature DB >> 637271

Circulatory effects of labetalol during halothane anaesthesia.

D B Scott, F P Buckley, D G Littlewood, W R Macrae, G R Arthur, G B Drummond.   

Abstract

Labetalol is a drug possessing both alpha and beta adrenergic receptor blocking properties. Its possible use in induced hypotension during halothane anaesthesia has been investigated. It causes a satisfactory decrease in arterial pressure unaccompanied by tachycardia. The circulatory effects of the drug during halothane anaesthesia, both with spontaneous and controlled respiration, have been measured and compared with those of halothane alone. In patients anaesthetised with 1% halothane, labetalol, with both spontaneous and controlled ventilation, was associated with a reduction in MAP from 71.5 mmHg to 54.0 mmHg (P less than 0.001) and 66.8 mmHg to 50.4 mmHg (P less than 0.001) respectively. This reduction was associated with decreases in Qt of 18% and 12% respectively. In the presence of labetalol, with 3% halothane and spontaneous respiration, the depressant effects of the anaesthetic on the heart became rapidly apparent: Qt was reduced by a further 28%. In patients not receiving labetalol, the depressant effects of 3% halothane were frequently countered by the positive inotropic effects of hypercarbia.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 637271     DOI: 10.1111/j.1365-2044.1978.tb08342.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  5 in total

1.  Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

2.  Use of labetalol during halothane anaesthesia.

Authors:  D H Cope
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

Review 3.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

4.  The use of labetalol in anaesthesia.

Authors:  D B Scott
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

5.  Use of labetalol during hypotensive anaesthesia and in the management of phaeochromocytoma.

Authors:  L Kaufman
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.